Uniqure (QURE) Osake Kurssi

Uniqure NV is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Uniqure NV in the market are established companies such as Pfizer and Novartis. These pharmaceutical giants also specialize in gene therapy and have a significant presence in the biotechnology industry. Uniqure NV, a pioneering company in gene therapy, competes with these industry leaders in the development and commercialization of innovative treatments for genetic disorders. Their expertise and advancements in gene therapy contribute to the company's growth and sustenance in a fiercely competitive market.

Uniqure NV is a pioneering gene therapy company that has made significant contributions in the field of genetic medicine. Founded in 1999, Uniqure NV has been dedicated to developing innovative treatments for rare genetic diseases and has successfully brought several therapies to market. With a focus on gene therapy platforms, the company has demonstrated its expertise in delivering long-lasting therapeutic effects. Uniqure NV has collaborated with leading research institutes and pharmaceutical companies to advance the field of gene therapy. Its commitment to improving patient outcomes through groundbreaking therapies has earned Uniqure NV a prominent position in the biotechnology industry.

Uniqure NV, a leading biopharmaceutical company, has achieved several significant milestones. It pioneered gene therapy and became the first company to gain approval for a gene therapy product in the European Union. Furthermore, Uniqure NV successfully launched Glybera, a groundbreaking treatment for patients with lipoprotein lipase deficiency. The company also forged strategic collaborations with top pharmaceutical companies to advance gene therapies for various diseases. Uniqure NV's dedication to innovation and its groundbreaking achievements have positioned the company as a pioneering force in the field of gene therapy, driving advancements in healthcare and offering hope for patients worldwide.

Uniqure NV is primarily present in various countries and regions across the globe. Some key locations where the company has a significant presence include the United States, Europe, and Canada. With its headquarters in the Netherlands, Uniqure NV has a strong foothold in Europe, particularly in countries like Germany, France, and the United Kingdom. Additionally, the company has expanded its reach to North America, with operations in the United States and Canada. Uniqure NV's global presence allows it to engage with a diverse range of markets and customers, facilitating its growth and impact in the field of genetic therapies.

Uniqure NV represents values of pioneering gene therapies and a commitment to transforming the lives of patients with severe genetic diseases. The company's corporate philosophy is centered around innovation, scientific excellence, and patient-centricity. Uniqure NV is dedicated to developing and delivering breakthrough treatments utilizing its proprietary gene therapy platform, focusing on addressing unmet medical needs. With a strong emphasis on collaboration and partnerships, Uniqure NV strives to advance the field of gene therapy, offering hope and improved quality of life to individuals affected by rare genetic disorders.

Analyytikot asettavat tällä hetkellä Uniqure-osakkeelle keskimääräisen tavoitehinnan 57,50 USD (mediaani: 60,50 USD), mikä merkitsee +163,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.

Uniqure Analyytikkojen kursstavoitteet 2026

20 analyytikkoa arvioi tällä hetkellä Uniqure-osaketta: 18 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Uniqure-yhtiöltä 23,45 M USD liikevaihtoa ja −3,89 USD osakekohtaista tulosta.

Uniqure Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Uniqure-osake noteerataan hintaan 19,55 EUR (21,86 USD).

Uniqure-osake (QURE) on listattuna 6 pörssissä, muun muassa: NASDAQ (QURE), London (0EE0.L), SIX (Zürich) (UQ1.SW), XETRA (UQ1.DE), Frankfurt (UQ1.F).

Uniqure NV is a leading biotechnology company specializing in the development of innovative gene therapies for genetic diseases. The company utilizes its proprietary gene therapy platform to develop life-changing therapies for patients in various therapeutic areas. The business model of Uniqure is based on collaboration with leading academics and companies in the biotech industry, as well as its own research and development strategy. The company has a variety of partnerships with pharmaceutical and biotech companies to expand its portfolio of gene therapy products and bring them to market. Uniqure is one of the few companies using gene editing technology to treat genetic diseases. This technology allows for the correction or replacement of specific genes in human cells. This is a breakthrough in gene therapy, as previous approaches often only provided symptomatic treatment. Uniqure's product portfolio currently includes a wide range of gene therapy products in various stages of clinical development and therapeutic areas. Some of these therapies are already in phase III clinical trials, focusing on diseases such as hemophilia, Huntington's disease, and spinal muscular atrophy. Uniqure also focuses on developing gene therapies for rare diseases that have been previously unmet medical needs. These niche markets offer enormous opportunities for the company, as they are often overlooked by other companies due to their low potential. The business model of Uniqure also includes a strong patent and technology protection strategy to ensure long-term competitiveness. The company places a strong emphasis on regulatory compliance and collaboration with regulatory authorities to facilitate the approval of its treatment products. The company has a variety of financing options, including venture capital and public financing. Uniqure also has a strong partnership with multinational pharmaceutical companies such as Bristol-Myers Squibb, who support the company in bringing its gene therapy products to the global market. Overall, the business model of Uniqure NV offers a wide range of innovative gene therapies for the treatment of genetic diseases, as well as a strong protection strategy for its technologies and patents. With strong partnerships and a broad research and development strategy, the company offers enormous opportunities for growth in the coming years.

odotettu liikevaihto Uniqure on 23,45 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Uniqure on −223,84 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Uniqure:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,62. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Uniqure-osakkeen arvostusta.

Uniqure:n hinta-myynti-suhde (P/S) on tällä hetkellä 53,60. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Uniqure-osakkeen arvostuskennuslukuna.

Uniqure:n Eulpool-laatuscore on 1/10.

Uniqure:n ISIN on NL0010696654. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Uniqure:n WKN on A1XDTV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Uniqure:n ticker on QURE. Tämä pörssinoteeraus käytetään Uniqure-osakkeiden kauppaan pörssissä.